Neuren Pharmaceuticals Ltd
ASX:NEU

Watchlist Manager
Neuren Pharmaceuticals Ltd Logo
Neuren Pharmaceuticals Ltd
ASX:NEU
Watchlist
Price: 12.635 AUD 1.32%
Market Cap: 1.6B AUD

Neuren Pharmaceuticals Ltd
Investor Relations

Founded in 1993, Neuren Pharmaceuticals Ltd has carved a niche for itself within the biotech industry, focusing primarily on neurological and neurodevelopmental disorders. The company operates at the intriguing intersection of innovation and medicine, where the stakes are high, but so are the potential rewards. Neuren has its headquarters in Australia and has oriented its research towards developing therapies that could change the lives of those affected by conditions like Rett syndrome and Fragile X syndrome. By adopting a strategic approach that combines cutting-edge science with a relentless focus on unmet needs, Neuren positions itself uniquely through its proprietary compounds such as trofinetide and NNZ-2591, which are at the core of its research endeavors.

The company's business model hinges on a dual approach: developing its own drugs while simultaneously fostering partnerships with larger pharmaceutical companies to bring these therapies to market. This model allows Neuren to share the substantial costs and risks inherent in drug development while benefiting from the expanse of its partners' distribution networks and market insights. Revenue generation kicks in primarily through milestone payments, royalties, and licensing agreements as these partners help navigate the rigorous phases of clinical trials and regulatory approvals. Financial stability is thus intricately tied to clinical successes and strategic alliances, allowing Neuren to balance the speculative nature of biotech investments with the promise of transformative medical breakthroughs.

Show more
Loading

Earnings Calls

2024 Q4
Feb 28, 2025
Show Transcript
Previous
Next
Strong Q4 leads to optimistic growth outlook for Pembina
2024 Q4
Feb 28, 2025

Pembina reported a robust Q4, ending the year positively with over $4 billion in secured projects, suggesting a strong growth trajectory. The company anticipates 4% to 6% compound annual growth rate (CAGR) through 2025, driven by increasing productivity and strong market demand. Notable projects like the Yellowhead Mainline expect to provide 25,000 barrels of natural gas liquids extraction capacity, with capital costs estimated between $400 million and $500 million. As they navigate regulatory discussions, Pembina maintains solid customer relationships and positions itself well for future expansions in a growing market.

Show Full Analysis

Management

Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.
CEO, MD & Executive Director
No Bio Available
Ms. Lauren Frazer C.A.
CFO & Company Secretary
No Bio Available
Mr. Lawrence Glass BA (Biology)
Chief Science Officer
No Bio Available
Mr. Gerry Zhao
Vice President of Corporate Development
No Bio Available
Dr. Liza A. Squires M.D.
Chief Medical Officer
No Bio Available

Contacts

Address
VICTORIA
Melbourne
SE 201 697 Burke Rd, Camberwell
Contacts
+61390920480.0
www.neurenpharma.com